Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.42 |
| ▸ | NOS2 | P35228 | 4/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8958622 | 1.00 | NOS1 (0.42) | NOS1NOS2NOS3KDM4EALDH1A1 | |
| SCHEMBL13560831 | 0.75 | CTDSP1 (0.42) | NOS1NOS2NOS3KDM4EALDH1A1 | |
| SCHEMBL4039458 | 0.75 | NOS3 (0.37) | NOS1NOS2NOS3KDM4EALDH1A1 | |
| SCHEMBL9860940 | 0.75 | NOS3 (0.37) | NOS1NOS2NOS3KDM4EALDH1A1 | |
| SCHEMBL14246443 | 0.75 | NOS1 (0.46) | NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL4039461 | 0.75 | NOS3 (0.37) | NOS1NOS2NOS3KDM4EALDH1A1 | |
| SCHEMBL27427946 | 0.75 | KDM4E (0.37) | NOS1NOS2NOS3KDM4EALDH1A1 | |
| SCHEMBL17816554 | 0.73 | NOS1 (0.36) | NOS1NOS2NOS3 | |
| SCHEMBL1133545 | 0.72 | NOS1 (0.52) | NOS1NOS2NOS3 | |
| SCHEMBL13576632 | 0.72 | NOS1 (0.47) | NOS1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8059568-A | — | — | None | — | — | JP | disclosed |
| JP-8059567-A | — | — | None | — | — | JP | disclosed |
| EP-3829559-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | Merck Sharp & Dohme Corp. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020028150-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-9411226-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9411226-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| JP-H0859567-A | PRODUCTION OF TRANS-4-ALKYLCYCLOHEXYLAMINE | NIPPON KASEI CHEM CO LTD | 1996-03-05 | — | — | JP | disclosed |
| JP-H0859568-A | PRODUCTION OF TRANS-4-ALKYLCYCLOHEXYLAMINE | NIPPON KASEI CHEM CO LTD | 1996-03-05 | — | — | JP | disclosed |
| EP-0121701-A1 | Process for the production of o-substituted oximes | ALLIED CORPORATION (US) | 1984-10-17 | — | — | EP | disclosed |
| US-4395413-A | NICOTINE ANTIALLERGEN, ANESTHETIC, ANALGESIC, HYPOTENSIVE, AND ANTIULCER AGENT | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1983-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | NOS1 3271/4885NOS2 3346/4885NOS3 3204/4885 |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | NOS1 3271/4885NOS2 3346/4885NOS3 3204/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | NOS1 3271/4885NOS2 3346/4885NOS3 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.